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OBJECTIVES We hypothesized that cytomegalovirus (CMV) infection: 1) stimulates an inflammatory
response, reflected by elevated C-reactive protein (CRP) levels, and 2) predisposes to coronary
artery disease (CAD), in part, through CMV-induced inflammation.
BACKGROUND Although some studies show an association between CMV and atherosclerosis, others do not.
We believed that CMV exerted an atherogenic effect by inducing inflammation, and the
disparate results may derive partly from individual variability in the capacity to control CMV
inflammatory activity.
METHODS Blood samples were tested for CMV seropositivity and CRP levels from 238 individuals being
evaluated for CAD by coronary angiography.
RESULTS An elevated CRP level (.0.5 mg/dl) was a significant CAD determinant even after
adjustment for traditional CAD risk factors (odds ratio [OR] 5 2.4; p 5 0.02). Moreover,
CMV seropositivity was significantly associated with increased CRP levels (p 5 0.04 after
adjustment for CAD risk factors), suggesting that CMV could evoke a subclinical inflam-
matory response. However, considerable host variation existed in this response to CMV.
When adjusted for CAD risk factors, the OR for CAD were 1.3 in the subgroup with CMV
seropositivity alone (p 5 0.7), 2.3 in the subgroup with elevated CRP levels alone (p 5 0.2),
and 4.3 in the subgroup with combined CMV seropositivity and elevated CRP levels (p 5
0.01).
CONCLUSIONS Our results suggest that 1) CMV elicits a subclinical inflammatory response, but only in
certain individuals, and 2) individuals with an inflammatory response appear susceptible to the
atherogenic effects of CMV, whereas those without appear resistant. These results may partly
explain the disparate results of studies attempting to relate CMV to atherogenesis. (J Am
Coll Cardiol 1999;34:1738–43) © 1999 by the American College of Cardiology
Multiple epidemiological studies have suggested that cyto-
megalovirus (CMV) infection plays a role in the develop-
ment of atherosclerosis. The data are not entirely consistent,
however; some studies show a significant association with
coronary artery disease (CAD) (1–8), and others do not
(9,10). Of possible relevance to this conundrum are three
considerations: 1) substantial evidence now exists indicating
that inflammation contributes to the atherogenic process
(11–18); 2) although the stimuli responsible for triggering
this inflammatory process are largely unknown, infectious
agents, such as CMV, may be one class of such stimuli; 3)
individuals vary in their response to infection; it is therefore
possible that a similar variation occurs in response to CMV
infection, with only certain individuals developing an in-
flammatory response, and therefore only a certain subset of
CMV-infected individuals being susceptible to any athero-
genic effects of the virus.
Given these considerations, we studied the possible in-
teractions that both infection and inflammatory response
have on CAD risk to gain further insight into the possible
role of CMV infection in CAD. The purpose of the present
investigation, therefore, was to examine the validity of the
following interrelated hypotheses: 1) CMV infection stim-
ulates an inflammatory response, as reflected by elevated
levels of C-reactive protein (CRP); 2) not all individuals
develop an inflammatory response to CMV infection; and
3) the likelihood of CMV infection predisposing to CAD is
importantly dependent on the development of an inflam-
matory response.
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METHODS
Patient characteristics. Two hundred thirty-eight individ-
uals were recruited for this study, which was approved by
the National Heart, Lung, and Blood Institute (NHLBI)
the Institutional Review Board (IRB). Each individual was
admitted to the Cardiology Branch, NHLBI, National
Institutes of Health, for evaluation of chest pain or possibly
abnormal noninvasive tests and underwent diagnostic cor-
onary angiography. We defined a patient as having CAD if
there was any angiographic evidence of atherosclerosis,
including plaquing in any segment of the epicardial coro-
nary tree. A patient was defined as being “free” of CAD only
if all coronary arteries were judged to be angiographically
smooth. Blood was drawn by venipuncture from each
patient. The serum was aliquoted and frozen at 280°C until
analyzed. No individual without CAD was admitted into
the study unless blood for testing was drawn within three
years of coronary angiography. No patient admitted to the
study had a myocardial infarction within the previous three
months. All patients with CAD were classified as having
stable CAD.
Determination of risk factors for CAD. Risk factors for
CAD that were analyzed included age, gender, cigarette
smoking, diabetes, hypercholesterolemia, hypertension,
CRP levels and seropositive CMV status. A history of past
and current cigarette smoking of each patient was obtained.
A patient who had stopped smoking more than 20 years ago
and who was less than 30 years of age when he or she
stopped smoking was considered not to have smoking as a
risk factor. A patient was considered to have diabetes if he
or she was taking insulin or oral hypoglycemic agents or had
previously received such treatment and was currently using
dietary modification to control the condition. A patient was
considered to have hypercholesterolemia if he or she had a
serum cholesterol value higher than 240 mg/dl (6.2 mmol/
liter) or was receiving cholesterol-lowering treatment. A
patient was considered to have hypertension if he or she had
received the diagnosis or was being treated with antihyper-
tensive medications and/or dietary modification.
Antibody status to CMV. Blood samples from each indi-
vidual were tested for anti-CMV IgG antibodies using an
enzyme-linked immunosorbent assay (ELISA, CYTO-
MEGELISA II, Biowhittaker, Walkersville, Maryland).
Antibody results were calculated from standard curves
provided by the manufacturer. The threshold value for a
“positive” result was determined prospectively: an ELISA
value ,0.25 units was considered a negative result, and a
value of $0.25 unit was considered positive, indicating prior
exposure to CMV. Samples for anti-CMV IgG antibodies
were tested in triplicate and in two separate experiments.
C-reactive protein. Serum CRP was measured by fluo-
rescence polarization immunoassay (FPIA) technology
(TDxFLEx analyzer, Abbott, Abbott Park, Illinois). Using
this assay, 95% and 98% of healthy individuals (n 5 202)
had a CRP level of #0.5 mg/dl and #1.0 mg/dl, respec-
tively, in their sera (19). The between-run coefficient of
variation (CV) of this assay (n 5 31) was 4.3% and 2.2% at
mean levels of 1.10 mg/dl and 2.94 mg/dl, respectively.
Statistical analysis. Categorical data were analyzed by the
chi-square test or the Fisher exact test for small samples. All
tests were two-sided. The dichotomous variable indicating
presence or absence of CAD was modeled as a function of
other factors or variables using multiple logistic regression.
The odds ratio (OR) was used as a measure of the risk of
CAD in patients with a given risk factor as compared to
those without that factor. In the case where age was the risk
factor, the OR measures the change in risk of CAD for a
ten-year increase in age. The covariates considered were age,
gender, cigarette smoking, diabetes, hypercholesterolemia,
hypertension, and seropositive CMV status. All covariates
were examined as predictors of both CRP level and the
presence of CAD in univariate analyses using the Pearson
correlation. A multivariate analysis of these covariates as
predictors of CAD was made using the Logistic procedure
of the SAS software system for PC Windows (20), which
computes the logistic regression of the dichotomous variable
CAD on age, gender, and other factors. The relationship
between CRP level, a continuous variable, and the values of
age, gender, and so forth, was analyzed using the General
Linear Model (GLM) procedure of SAS.
RESULTS
Association of CAD with traditional risk factors. Of the
238 study subjects, 151 (63%) were men and 87 (37%)
women. One hundred sixty-nine (71%) were white, 34
(14%) were black, 22 (9%) were Asian, and 13 (5%) were
unknown. Their ages ranged from 30 to 81 years (mean 57.2
years, median 57 years). There were 158 (66%) individuals
who had evidence of CAD ranging from plaquing to
significant stenoses by coronary angiography. By univariate
analysis, the factors that were significantly associated with
the presence of CAD were age (p 5 0.0001), male gender
(p 5 0.0002), smoking (p 5 0.008), diabetes (p 5 0.001)
and hypercholesterolemia (p 5 0.0004). Age, male gender
and hypercholesterolemia were retained as significant risk
factors after multivariate analysis (Table 1). Thus, our study
cohort was representative of a typical population of patients
with stable CAD.
Abbreviations and Acronyms
CAD 5 coronary artery disease
CMV 5 cytomegalovirus
CRP 5 C-reactive protein
OR 5 odds ratio
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Association of elevated CRP levels with CAD risk.
Elevated levels of CRP were found to be an important risk
factor for CAD, as shown in Figure 1. Mean CRP value was
significantly higher in patients with CAD, compared to
those without CAD (0.89 6 0.05 vs. 0.68 6 0.07 mg/dl,
p 5 0.01, Fig. 1A). Seventy-seven percent of patients with
CAD had CRP levels .0.5 mg/dl, versus 52% of patients
without CAD (0 5 0.001, Fig 1B). Elevated CRP level
remained a significant determinant of CAD after adjust-
ment for traditional CAD risk factors, including age, male
gender, smoking, diabetes, hypertension and hypercholes-
terolemia (OR 5 2.4, p 5 0.02).
Contribution of CMV infection to elevated CRP levels.
Of the 238 patients, 153 (64%) had positive tests for
anti-CMV IgG antibodies. Mean value of CRP was 0.88 6
0.05 mg/dl in CMV seropositive patients and 0.69 6
0.06 mg/dl in CMV seronegative patients (p 5 0.02). By
univariate analysis, the CRP level (as a continuous variable)
correlated with presence of hypercholesterolemia (p 5
0.006), hypertension (p 5 0.0008), and CMV seropositivity
(p 5 0.02), but not with age, male gender, smoking and
diabetes (all p .0.1). When adjusted for traditional CAD
risk factors, including age, male gender, smoking, diabetes,
hypertension and hypercholesterolemia, by multivariate
analysis an association between CRP level and CMV
seropositivity retained statistical significance (p 5 0.04,
Table 2), suggesting that CMV infection is an independent
determinant of CRP levels.
Association between CMV seropositivity and CAD risk.
On univariate analysis, CMV seropositivity was significantly
associated with CAD (p 5 0.02). Of 158 patients with
CAD, 110 (70%) had anti-CMV IgG antibodies, whereas
Figure 1. (A) Mean levels of CRP in patients with CAD and in patients without coronary artery disease (CAD). Mean CRP values
(mg/dl 6 SE) are shown. (B) Prevalence of high CRP levels (.0.5 mg/dl) in patients with CAD and in patients without CAD. CAD1:
presence of CAD; CAD2: absence of CAD; CRP: C-reactive protein.
Table 1. Association of Traditional Risk Factors With Presence of CAD
Risk Factors
Frequency of Factors (%) Univariate Analysis
Multivariate
Analysis
Patients
With CAD
Patients Without
CAD
Pearson
Correlation
p
Value
Odds
Ratio
p
Value
Age* 0.3726 0.0001 2.340† 0.0001
Male gender 72 48 0.2356 0.0002 5.969 0.0005
Smoking 53 35 0.1737 0.0081 1.495 0.2451
Diabetes 22 5 0.2164 0.0010 3.025 0.0682
1Cholesterol 54 30 0.2284 0.0004 3.470 0.0007
Hypertension 49 40 0.0911 0.1669 0.951 0.8850
*Age as a continuous variable. †Odds ratio for age represents the increase in risk of CAD for each 10-year increase in age.
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only 43 of 80 (54%) of those with no evidence of CAD were
CMV seropositive (p 5 0.02, Fig. 2). In addition, we
carried out multiple logistic regression analysis to assess
determinants of CAD; covariants included traditional risk
factors, elevated CRP levels (.0.5 mg/dl) and CMV
seropositivity. We found that elevated CRP levels retained
a significant association with CAD (OR 5 2.3, p 5 0.02),
whereas the association of CMV seropositivity with CAD
lost significance (p 5 0.2).
Variation in the inflammatory response to CMV infec-
tion. Further analysis showed considerable variation in the
host’s inflammatory response (judged by elevated CRP
levels) to CMV infection: 111 of 153 (73%) of CMV-
seropositive individuals had elevated CRP levels (.0.5 mg/dl),
whereas the remainder of the seropositive individuals (27%)
had CRP values ,0.5 mg/dl. Figure 3 shows the influence of this variability on the relation between CMV seroposi-
tivity and CAD prevalence. There is a stepwise increase in
the prevalence of CAD depending on CMV seropositivity
and/or elevated CRP levels. The highest CAD prevalence
occurred in the subgroup with combined seropositivity and
elevated CRP levels (83/107, 78%). However, only 22%
(24/107) of individuals without CAD had both CMV
seropositivity and elevated CRP levels. When adjusted for
CAD risk factors, the ORs for CAD were 1.3 (95% CI
[confidence interval], 0.4 to 4.4; p 5 0.7) in the subgroup
with CMV seropositivity alone, 2.3 (95% CI, 0.7 to 7.5; p 5
0.2) in the subgroup with elevated CRP levels alone, and 4.3
(95% CI, 1.4 to 13.1; p 5 0.01) in the subgroup with
combined CMV seropositivity and elevated CRP levels.
The overall stepwise increase in CAD prevalence remained
significant by multiple logistic regression analysis (p 5
0.0016).
DISCUSSION
The hypotheses we prospectively tested in this investigation
were designed to provide insight into both the mechanisms
by which infection, and in particular CMV, might contrib-
ute to CAD, and why the results of multiple epidemiolog-
ical studies assessing the potential role of CMV in CAD
have not been entirely consistent (1–10). These hypotheses
Figure 2. Prevalence of seropositivity to CMV in patients with
CAD and in patients without CAD. CAD1: presence of CAD;
CAD2: absence of CAD.
Figure 3. Prevalence of CAD among subgroups with variation in
inflammation and CMV infection. When adjustment for CAD
risk factors, the odds ratios for CAD were 1.3 (95% CI, 0.4 to 4.4;
p 5 0.7) in the subgroup with CMV seropositivity alone, 2.3 (95%
CI, 0.7 to 7.5; p 5 0.2) in the subgroup with elevated CRP levels
alone, and 4.3 (95% CI, 1.4 to 13.1; p 5 0.01) in the subgroup
with combined CMV seropositivity and elevated CRP levels.
Overall liner trend achieves significance even after adjustment for
CAD risk factors (p 5 0.0016). CMV Ab1 or CMV Ab2: CMV
antibody response positive or negative, respectively; CRP .0.51
or CRP .0.52: CRP levels .0.5 mg/dl or CRP levels
#0.5 mg/dl, respectively.
Table 2. Association of CAD Risk Factors With CRP*
Risk Factors
Univariate Analysis Adjusted†
Pearson
Correlation
p
Value
p
Value
Age* 0.0849 0.1917 0.3887
Male gender 0.0568 0.3834 0.4018
Smoking 0.0855 0.1956 0.5449
Diabetes 0.0233 0.7261 0.3881
1Cholesterol 0.1778 0.0063 0.0434
Hypertension 0.2178 0.0008 0.0032
CMV seropositivity 0.1485 0.0219 0.0443
*As a continuous variable. †Adjusted for traditional CAD risk factors.
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were predicated on the concepts that CMV stimulates an
inflammatory response in the host, that such a response varies
among hosts, and that the presence or absence of an inflam-
matory response will importantly influence risk of CAD
prevalence. Our results are consistent with these hypotheses.
Relation among CRP levels, CMV infection, and CAD.
We demonstrated an association between antibodies to
CMV and elevated CRP levels, as reflected by the observa-
tion that higher CRP levels were present in CMV-
seropositive versus CMV-seronegative individuals (0.88
versus 0.69 mg/dl). This difference retained significance
even on multivariate analysis after adjustment for traditional
CAD risk factors, including age, male gender, smoking,
diabetes and hypercholesterolemia (p 5 0.04), suggesting
that CMV infection is an independent determinant of
elevated CRP levels and, by inference, predisposes to the
induction of chronic subclinical inflammation in the host.
Importantly, however, we also found that not all hosts
respond in this way; of the CMV-seropositive individuals,
27% did not have elevated levels of CRP.
This variation in the inflammatory response of the host to
CMV infection likely has important biologic consequences,
for in our total cohort, although CMV infection was not an
independent determinant of CAD risk, CRP elevation was.
Consistent with the concept that the presence or absence of
an inflammatory response to CMV infection importantly
influences CAD risk is the finding of a stepwise increase in
the prevalence of CAD depending on a positive interaction
between CMV seropositivity and elevated CRP levels (Fig.
3). The highest CAD prevalence (78%) occurred in the
subgroup with combined seropositivity and elevated CRP
levels, providing an OR for CAD of 4.3 (p 5 0.01),
compared to an OR of 1.3 in the subgroup with CMV
seropositivity alone (p 5 0.7), and 2.3 in the subgroup with
elevated CRP levels alone (p 5 0.2). The overall stepwise
increase in CAD prevalence remained significant by multiple
logistic regression analysis (p 5 0.0016). Thus, one mechanism
by which CMV may contribute to atherogenesis is through
provocation of an inflammatory response in the host.
Our results also provide a potential explanation for the
conflicting evidence relating to the role of CMV in athero-
sclerosis, as it appears that the particular nature of the host’s
inflammatory response is one important determinant of
whether CMV contributes to CAD. This conclusion im-
plies that studies assessing whether CMV infection (or
probably any infectious agent) is associated with CAD must
take into consideration the frequency with which infection
leads to inflammation in the particular cohort being studied.
It could be anticipated that on the basis of genetic, envi-
ronmental, or selection factors, different populations being
studied may exhibit different dominant modes of respond-
ing to a specific infection—the dominant response of one
population may be to develop an inflammatory response,
whereas such a response may be absent in another popula-
tion. Whether or not an inflammatory response evolves may in
turn depend on the type of immune response that develops—
immunodominant humoral or immunodominant cellular.
Prior studies of CRP and CMV infection in CAD.
These considerations may relate to the apparently discor-
dant results between our study, which demonstrated a
significant association between CMV seropositivity and
elevated CRP levels, and the lack of such a significant
association in the study published by Anderson et al. (21),
who reported on the relation between seropositivity to three
pathogens—CMV, Chlamydia pneumoniae, and Helicobacter
pylori—and elevated CRP levels. They found, concordant
with the results of many other studies, that CRP levels were
significantly higher in individuals with CAD versus those
without CAD. They also reported no significant correlation
between CAD prevalence and seropositivity to any of the
pathogens, a result compatible with our findings. However,
in contrast to our results, Anderson et al. (21) could find no
significant association between elevated CRP levels and any
of the pathogens.
The disparate results between our study and that of
Anderson et al. (21) may also relate to the type of patient
included in each of the studies. In contrast to the inclusion
criteria for the individuals entered into the present study, in
which patients with recent myocardial infarction were ex-
cluded, Anderson et al. (21) did admit study patients with
recent infarction. Myocardial infarction by itself can cause
substantial increases in CRP levels. It is therefore possible
that the presence of this independent factor leading to
increased CRP levels exerted confounding influences ac-
counting for the failure to establish a significant association
between CMV seropositivity and elevated CRP levels. In
addition, there were differences in definition of CAD versus
no CAD between the two studies. Anderson et al. (21)
entered patients into the CAD group if they had .60%
stenoses, and into the no-CAD group if they had ,10%
stenoses. Individuals with intermediate stenoses (10% to
60%) were excluded from the study. In contrast, we defined
an individual as having CAD if there was any luminal wall
irregularity, and as being free of CAD only in the presence
of absolutely smooth coronary arteries on angiography.
Study limitations. The conclusions of the present investi-
gation must be placed in the context of several caveats. First,
the study design of this investigation is cross-sectional in
nature. Such a design cannot establish causality. It can only
establish an association. Any conclusion derived from such
a study must therefore be considered preliminary and
hypothesis-generating rather than hypothesis-proving. Second,
as implied in our discussion about different populations re-
sponding differently to a specific infection, the conclusion that
CMV contributes to CAD only insofar as it contributes to
inflammation may not be true for all individuals with CMV
infection and CAD. It is possible, for example, that certain
individuals who do not develop an inflammatory response to
CMV infection develop a type of immune response that might
in itself contribute to atherogenesis. Third, not all individuals
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who have elevated CRP levels and are seropositive for CMV
have associated CAD. This is consistent with the concept that
because CAD is a multifactorial disease, any one risk factor will
rarely be sufficient for disease development.
Finally, one of the strengths of our study is that our
control and patient groups were defined by coronary an-
giography, a far more accurate means of defining presence or
absence of CAD than the clinical parameters employed in
most seroepidemiologic studies. However, we cannot ex-
clude the possibility that some individuals considered to be
free of CAD had minimal disease that could not be detected
by angiography. In addition, our non-CAD control group
consisted of individuals who, on clinical evaluation, had
some suspicion of CAD. The absence of angiographically
evident CAD is definitive evidence that the findings leading
to angiography were not due to CAD; however, such
individuals may not be representative of other individuals
without CAD who lack clinical features triggering the
decision to perform coronary angiography.
Conclusions. The results of this investigation demonstrate
that although CMV infection is associated with elevated
CRP levels, individuals vary in their capacity to control
CMV inflammatory activity, as reflected by elevated CRP
levels. This variation appears to be biologically relevant, as
the risk of CAD is greatest in individuals who are seropos-
itive for CMV and who have elevated CRP levels. These
results are compatible with the hypothesis that susceptibility
to the atherogenic effects of CMV depends, at least in part,
on the capacity of the host to suppress CMV-induced
inflammatory activity. Based on these and related findings,
it is likely that a complete understanding of the potential
role of infection in CAD will be achieved only after the
more complex interrelations between a pathogen and the
host’s response to the pathogen are elucidated.
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